You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201531 - 201540 of 207726 results
  1. TOPIC 322 PHASE 1; REAL TIME INTEGRATION OF SENSOR AND SELF REPORT DATA FOR CLINI

    SBC: Vignet Inc.            Topic: NCI

    This proposal was submitted under the SBIR Fast-track process. In Phase I, the primary purpose is to develop a sensor-enhanced health information system for many different health contexts including prevention and management of chronic diseases such as cancers. In Phase II, Vignet will combine several innovative technologies and methods into a comprehensive, integrated, end-to-end sensor-enhanced d ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. The proposed research uses mobile and digital technology to provide real-time dat

    SBC: ZANSORS LLC            Topic: NCI

    The primary purpose is to develop a real-time method of monitoring lymphedema patients symptoms to be used with a smartphone or tablet when the patients are away from their clinic. The Offeror has set three substantial objectives for this prototype platform (see below). The technologies will be developed using both open-source and proprietary components and will provide an innovative way to colle ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. TOPIC 324 PHASE I 9 MONTH FUNDING; NOVEL IMAGING AGENTS T EXPAND TE CLINICAL TOOL

    SBC: ROCKLAND IMMUNOCHEMICALS, INC.            Topic: NCI

    Medical imaging and targeted therapy are the central components in the clinical management of cancer patients. Rockland Immunochemicals, Inc. is teaming up with Abzyme Therapeutics LLC to develop novel imaging agents that can be used in both cancer diagnosis and targeted therapy. In this phase I proposal, high-affinity camelid single domain antibodies to three cancer biomarkers HER2, EGFR and meso ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Contract Title: SBIR Phase I Topic 324 Development of an Imaging Agent Targeting

    SBC: MABVAX THERAPEUTICS, INC.            Topic: NCI

    The carbohydrate antigen sialyl-Lewis a (sLea), also known as CA19.9, is widely expressed in pancreatic cancer (PC), and serum CA19.9 expression is used as a tumor marker in PC. sLea serves as a ligand for E-selectin adhesion molecules and over-expressionof sLea may be a key event in invasion and metastasis. We have generated a series of fully human monoclonal antibodies (mAb) and 5B1 (IgG1/and#95 ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. SBIR Topic 314- High Content Screening of 3D Cultured Cancer Cells

    SBC: BioTime, Inc.            Topic: NCI

    Not Available

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. IGF::OT::IGF Compact, Low-Cost, High-Intensity Superconducting Isochronous Cyclot

    SBC: T Antaya, LLC            Topic: NCI

    Not Available

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. TOPIC 324 PHASE I; NOVEL IMAGING AGENTS TO EXPAND THE CLINICAL TOOL KIT FOR CANCE

    SBC: EVORX TECHNOLOGIES, INC.            Topic: NCI

    Targeted molecular imaging of cancer is vital for better personalized medicine, but requires novel imaging agents that recognize key molecular surface cell markers. Her2 is overexpressed in 20-30% of breast cancer and is targeted by Herceptin, yet no molecular imaging agent for Her2 is clinically approved. We propose to use Scanning Unnatural Protease Resistant (SUPR) peptides to develop a novel H ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. TOPIC 324 PHASE I NOVEL IMAGING AGENTS TO EXPAND THE CLINICAL TOOLKIT FOR CANCER

    SBC: INNOSENSE CORPORATION            Topic: NCI

    This project aims to demonstrate the feasibility of an in vivo diagnostic platform for recognizing indicators of tumor-microenvironment, unambiguously, in biological fluids, tissue phantoms and small animal imaging. Specific project aims are to synthesizeand evaluate cancer-specific, thermoresponsive, nanoparticle-based, near-infrared (NIR) fluorescent contrast agents (ThermoDots) for optical imag ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. IGF::OT::IGF Laser-driven Proton and Carbon Therapy

    SBC: RADIABEAM TECHNOLOGIES, LLC            Topic: NCI

    Not Available

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. IGF::OT::IGF Title: SMART Fusion: High Affinity Peptide Capture Reagents PoP: 0

    SBC: A&G PHARMACEUTICAL, INC.            Topic: NCI

    The purpose of this application is to develop realiable, renewable, cost effective, specific, high affinity antipeptide affitnity reagent to be successfully used in mass spec based cancer biomarker detection methods such as SISCAPA, for the analysis of patient plasma. Early detection of cancer is a key to successful and cost effective treatment. Routine monitoring of the plasma biomaker levels is ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government